NCT02840487View on ClinicalTrials.gov

Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 2, 2016

Primary Completion Date

March 14, 2019

Study Completion Date

March 14, 2019

Conditions
Prevention of Zika InfectionZika-Specific Immune Response
Interventions
BIOLOGICAL

VRC-ZKADNA085-00-VP

VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

Trial Locations (3)

20892

National Institutes of Health Clinical Center, Bethesda

21201

University of Maryland Ctr. for Vaccine Development, Baltimore

30030

Hope Clinic - Emory Vaccine Ctr, Decatur

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02840487 - Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults | Biotech Hunter | Biotech Hunter